A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
advanced solid tumors
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Dose-Response Relationship, Drug
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info